WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526682
CAS#: 393514-24-4
Description: BCTC is an orally effective vanilloid receptor 1 (TRPV1 receptor) antagonist. Inhibits acid- and capsaicin-induced activation of rat TRPV1 receptors (IC50 values are 6.0 and 35 nM respectively). BCTC significantly reduced the accompanying thermal and mechanical hyperalgesia (3 mg/kg and 10 mg/kg p.o., respectively). BCTC also reduced mechanical hyperalgesia and tactile allodynia 2 weeks after partial sciatic nerve injury (10 and 30 mg/kg p.o.). BCTC did not affect motor performance on the rotarod after administration of doses up to 50 mg/kg p.o.
Hodoodo Cat#: H526682
Name: BCTC
CAS#: 393514-24-4
Chemical Formula: C20H25ClN4O
Exact Mass: 372.17
Molecular Weight: 372.897
Elemental Analysis: C, 64.42; H, 6.76; Cl, 9.51; N, 15.03; O, 4.29
Synonym: BCTC
IUPAC/Chemical Name: 4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide
InChi Key: ROGUAPYLUCHQGK-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H25ClN4O/c1-20(2,3)15-6-8-16(9-7-15)23-19(26)25-13-11-24(12-14-25)18-17(21)5-4-10-22-18/h4-10H,11-14H2,1-3H3,(H,23,26)
SMILES Code: O=C(N1CCN(C2=NC=CC=C2Cl)CC1)NC3=CC=C(C(C)(C)C)C=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 372.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Liu T, Fang Z, Wang G, Shi M, Wang X, Jiang K, Yang Z, Cao R, Tao H, Wang X, Zhou J. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2016 Jan;11(1):182-188. Epub 2015 Nov 2. PubMed PMID: 26870186; PubMed Central PMCID: PMC4727066.
2: Yan L, Wang J, Pan M, Qiu Q, Huang W, Qian H. Synthesis of Analogues of BCTC Incorporating a Pyrrolidinyl Linker and Biological Evaluation as Transient Receptor Potential Vanilloid 1 Antagonists. Chem Biol Drug Des. 2016 Feb;87(2):306-11. doi: 10.1111/cbdd.12661. Epub 2015 Oct 5. PubMed PMID: 26360809.
3: Benko R, Illényi L, Kelemen D, Papp R, Papp A, Bartho L. Use and limitations of three TRPV-1 receptor antagonists on smooth muscles of animals and man: a vote for BCTC. Eur J Pharmacol. 2012 Jan 5;674(1):44-50. doi: 10.1016/j.ejphar.2011.10.021. Epub 2011 Oct 25. PubMed PMID: 22056835.
4: Tékus V, Bölcskei K, Kis-Varga A, Dézsi L, Szentirmay E, Visegrády A, Horváth C, Szolcsányi J, Petho G. Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath. Eur J Pharmacol. 2010 Sep 1;641(2-3):135-41. doi: 10.1016/j.ejphar.2010.05.052. Epub 2010 Jun 8. PubMed PMID: 20534382.
5: Valenzano KJ, Grant ER, Wu G, Hachicha M, Schmid L, Tafesse L, Sun Q, Rotshteyn Y, Francis J, Limberis J, Malik S, Whittemore ER, Hodges D. N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. J Pharmacol Exp Ther. 2003 Jul;306(1):377-86. Epub 2003 Apr 29. PubMed PMID: 12721338.
6: Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003 Jul;306(1):387-93. Epub 2003 Apr 29. PubMed PMID: 12721336.